Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Shunichiro Kuramitsu"'
Autor:
Yoshitaka Nagashima, Yoshio Araki, Kazuki Nishida, Shunichiro Kuramitsu, Kenichi Wakabayashi, Shinji Shimato, Takeshi Kinkori, Toshihisa Nishizawa, Takahisa Kano, Toshinori Hasegawa, Atsushi Noda, Kenko Maeda, Yu Yamamoto, Osamu Suzuki, Naoki Koketsu, Takeshi Okada, Masashige Iwasaki, Kiyo Nakabayashi, Shigeru Fujitani, Hideki Maki, Yachiyo Kuwatsuka, Masahiro Nishihori, Takafumi Tanei, Tomohide Nishikawa, Yusuke Nishimura, Ryuta Saito, Tokai Neurosurgical disorder Research Group CSDH Study investigators
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background The surgical techniques for treatment of chronic subdural hematoma (CSDH), a common neurosurgical condition, have been discussed in a lot of clinical literature. However, the recurrence proportion after CSDH surgery remains high,
Externí odkaz:
https://doaj.org/article/00b8ebfd4674490bb757dfe54262849d
Autor:
Daniel Alejandro Vega-Moreno, Shunichiro Kuramitsu, Eguchi Kaoru, Kajita Yasukazu, Ulises García-González, Abraham Ibarra-de la Torre, Liliana Hernández-Hernández, Rosa María Vicuña-González, Martha Elena González-Jiménez
Publikováno v:
World Neurosurgery: X, Vol 22, Iss , Pp 100306- (2024)
Background: Melanoma metastases to the CNS rank third in frequency, just after lung and breast metastases. There is controversy regarding the factors predisposing to developing CNS metastases in patients with cutaneous melanoma and their survival wit
Externí odkaz:
https://doaj.org/article/341f7dae8268461c9f2c036c80d8819d
Autor:
Lushun Chalise, Akira Kato, Masasuke Ohno, Sachi Maeda, Akane Yamamichi, Shunichiro Kuramitsu, Satoshi Shiina, Hiromi Takahashi, Sachiko Ozone, Junya Yamaguchi, Yukinari Kato, Yumi Rockenbach, Atsushi Natsume, Tomoki Todo
Publikováno v:
Molecular Therapy: Oncolytics, Vol 26, Iss , Pp 265-274 (2022)
Glioblastoma is a devastating malignant brain tumor with a poor prognosis despite standard therapy. Podoplanin (PDPN), a type I transmembrane mucin-like glycoprotein that is overexpressed in various cancers, is a potential therapeutic target for the
Externí odkaz:
https://doaj.org/article/245c987ac1fb490c848f5a0ad8a05f69
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the lack of truly tumor-specific target antigens, which translates to the targeting of tumor-associated antigens (TAAs) overexpressed on tumors but shared with nor
Externí odkaz:
https://doaj.org/article/e240ef07e6e44518b60174328e1690b0
Autor:
Yu Sugiyama, Shunichiro Kuramitsu, Kaoru Eguchi, Masashi Ito, Ryo Ando, Hiroki Matsuno, Noriyuki Suzaki, Satoshi Maesawa
Publikováno v:
Journal of Neurosurgery Case Lessons; Apr2024, Vol. 7 Issue 15, p1-5, 5p
Autor:
Keisuke Watanabe, M. Angela Aznar, Shunichiro Kuramitsu, Mikko Siurala, Tong Da, Sangya Agarwal, Decheng Song, John Scholler, Antonia Rotolo, Avery D Posey, Alain H Rook, Paul L. Haun, Marco Ruella, Regina M. Young, Carl H June
Publikováno v:
Blood Advances.
A challenge when targeting T cell lymphoma with chimeric antigen receptor (CAR) T cell therapy is that target antigens are often shared between T cells and tumor cells, resulting in fratricide between CAR T cells and on-target cytotoxicity on normal
Autor:
Marco Ruella, Saar Gill, Carl H. June, Stephan A. Grupp, Shannon L. Maude, Noelle V. Frey, Matthew D. Weitzman, Ophir Shalem, Shelley L. Berger, Charly R. Good, Karen Thudium Mueller, Elena J. Orlando, Shunichiro Kuramitsu, Sangya Agarwal, Raymone Pajarillo, Xueqing Maggie Lu, Seok Jae Hong, Katharina E. Hayer, Pranali Ravikumar, Olga Shestova, Yong Gu Lee, Nathan Singh
GSEA of transcriptomic and epigenomic sequencing of CART19 cells exposed to either WT or BIDKO Nalm6.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25883222ffed310d8a63d3bccdf5ab20
https://doi.org/10.1158/2159-8290.22535486
https://doi.org/10.1158/2159-8290.22535486
Autor:
Marco Ruella, Saar Gill, Carl H. June, Stephan A. Grupp, Shannon L. Maude, Noelle V. Frey, Matthew D. Weitzman, Ophir Shalem, Shelley L. Berger, Charly R. Good, Karen Thudium Mueller, Elena J. Orlando, Shunichiro Kuramitsu, Sangya Agarwal, Raymone Pajarillo, Xueqing Maggie Lu, Seok Jae Hong, Katharina E. Hayer, Pranali Ravikumar, Olga Shestova, Yong Gu Lee, Nathan Singh
Genes used to define exhaustion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da75f539064b5fc6909069d197b0e958
https://doi.org/10.1158/2159-8290.22535471
https://doi.org/10.1158/2159-8290.22535471
Autor:
Atsushi Natsume, Darell D. Bigner, Vidyalakshmi Chandramohan, Yukinari Kato, Mika K. Kaneko, Toshihiko Wakabayashi, Michinari Hamaguchi, Takeshi Senga, Ichiro Ito, Reiko Watanabe, Takashi Yamamoto, Kuniaki Tanahashi, Kazuya Motomura, Akira Kato, Akane Yamamichi, Shunichiro Kuramitsu, Fumiharu Ohka, Masasuke Ohno, Satoshi Shiina
(A) Non-specific killing was also excluded by the observation that EGFRvIII-targeting (3C10)-CAR PBMCs did not display significant lysis to LN319 cells. (B) The FACS-sorted CAR-T cells were subjected to RT-PCR. TNF-α was significantly produced in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a40f7fee58b29d85d639ff88e744099
https://doi.org/10.1158/2326-6066.22538161
https://doi.org/10.1158/2326-6066.22538161
Autor:
Marco Ruella, Saar Gill, Carl H. June, Stephan A. Grupp, Shannon L. Maude, Noelle V. Frey, Matthew D. Weitzman, Ophir Shalem, Shelley L. Berger, Charly R. Good, Karen Thudium Mueller, Elena J. Orlando, Shunichiro Kuramitsu, Sangya Agarwal, Raymone Pajarillo, Xueqing Maggie Lu, Seok Jae Hong, Katharina E. Hayer, Pranali Ravikumar, Olga Shestova, Yong Gu Lee, Nathan Singh
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy (CART19) occurs in 10% to 20% of patients with acute lymphoblastic leukemia (ALL); however, the mechanisms of this resistance remain elusive. Using a genome-wide loss-of-fun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecf6af83736892bbacd5098c738d5df9
https://doi.org/10.1158/2159-8290.c.6547871.v1
https://doi.org/10.1158/2159-8290.c.6547871.v1